USP 795 Nonsterile Compounding: Diversion Risks in the Compounding Area

Nonsterile compounding under USP 795 creates accountability gaps that diversion prevention programs frequently underestimate. Unlike commercially manufactured dosage forms with clearly defined unit counts, compounded preparations involve raw ingredient weights, intermediate steps, and finished quantities that all require rigorous documentation to produce a defensible audit trail. When that documentation is incomplete or inconsistent, controlled substances can disappear without a clear paper trail pointing to how or when.

What USP 795 Covers

USP Chapter <795> establishes standards for the preparation of nonsterile compounded drug preparations. Nonsterile compounding encompasses dosage forms prepared without sterility requirements: oral solutions and suspensions, capsules, troches and lozenges, suppositories, topical creams and ointments, and similar preparations. These are prepared from bulk pharmaceutical ingredients, commercially available drug products, or a combination of both.

While USP 795 itself focuses on quality and safety standards for compounded preparations — beyond-use dating, ingredient testing, facility requirements, documentation — the controlled substance accountability requirements that run alongside USP 795 are imposed by the DEA under 21 C.F.R. Parts 1301–1321 and by applicable state board of pharmacy regulations. A compounding pharmacy that follows USP 795 quality standards but fails to meet DEA accountability requirements is non-compliant on a separate and equally serious dimension.

How Nonsterile Compounding Creates Diversion Opportunity

Nonsterile compounding introduces diversion risk at multiple points in the preparation workflow that do not exist with pre-packaged commercially manufactured products. The key vulnerability points are:

• Ingredient weighing: The compounder weighs out bulk controlled substance ingredient (e.g., oxycodone powder, hydrocodone bitartrate, diazepam) from a larger supply. The difference between what was weighed out for the batch and what the balance log records is a potential diversion point. A compounder who consistently weighs out slightly more than the formula requires can skim the excess without an obvious finished-product discrepancy.
• Preparation steps: During mixing, filling, and other preparation steps, the controlled ingredient is in its rawest, least-trackable form. Intermediate product losses — whether genuine preparation losses or diversion — must be expected, quantified, and documented to distinguish one from the other.
• Finished unit counting: When capsules are filled, troches are formed, or liquid is filled into containers, the expected finished-unit yield must match the quantity of controlled ingredient that entered the preparation. If a batch produces fewer finished units than the formula predicts, the discrepancy must be explained and documented.
• Excess preparation: Compounders occasionally prepare slightly more than the ordered quantity to ensure adequate yield. The disposition of any excess controlled-substance-containing preparation must be documented — whether it is wasted, held for the next dispense, or returned to the bulk container.

Common Discrepancy Types in Nonsterile Compounding

The discrepancies that emerge most frequently in nonsterile compounding areas involve:

• Ingredient weight discrepancies: The amount of controlled ingredient recorded on the compounding log does not match the amount deducted from the bulk container's running balance. Even small, recurring weight differences accumulate into significant quantities over time.
• Finished-count shortfalls: The number of finished dosage units (capsules, troches, suppositories) produced from a batch is fewer than the formula predicts, without a documented explanation for the yield loss.
• Beyond-use date (BUD) discrepancies: Preparations whose BUD has expired should be returned to the pharmacy for destruction or waste documentation. When expired compounded controlled substances disappear without waste documentation, the discrepancy is a diversion flag.
• Patient-specific preparation overages: Compounding for a specific patient prescription frequently produces more finished product than the prescription calls for. The disposition of the overage — typically waste or destruction — must be documented contemporaneously.

Documentation Requirements for Compounded Controlled Substances

The compounding record — required by USP 795 for quality purposes — must also serve as the controlled substance accountability record for DEA purposes. A complete compounding record for a preparation containing a controlled substance must capture:

• The date of preparation
• The formula used (ingredient names, strengths, and quantities by weight or volume)
• The lot number and expiration date of each controlled substance ingredient used
• The quantity of controlled substance ingredient actually weighed or measured (not just the formula target — the actual balance reading)
• The identity of the compounder and the pharmacist who verified the preparation
• The final yield: the actual number of finished dosage units produced
• The expected yield based on the formula, and an explanation of any deviation between expected and actual yield
• The prescription number or batch identifier linking the preparation to the patient record
• The BUD assigned to the preparation

This document must be retained with your other controlled substance records under the two-year minimum retention rule (or the applicable state minimum, whichever is longer).

Labeling and Finished-Unit Accountability

Every finished compounded preparation containing a controlled substance must be labeled in compliance with DEA requirements for the dispensed product — not just USP 795 labeling requirements. The label must include the controlled substance name and strength, the patient name (for patient-specific preparations), the prescriber, the pharmacy, and the quantity dispensed.

For batch-compounded preparations (where the pharmacy prepares a quantity in advance of specific patient orders), each container of finished preparation that leaves the compounding area for dispense must be tracked to a specific dispense event. Batch preparations that are not immediately dispensed represent a controlled substance inventory obligation — the quantity on hand must be maintained in the perpetual inventory and must reconcile with batch records and dispense records.

Practical Accountability Controls for the Compounding Area

The following controls close the most common accountability gaps in nonsterile compounding of controlled substances:

• Two-person verification at weighing. Require a second pharmacist or trained compounder to verify and initial the balance weight at the time of controlled substance ingredient weighing — not after the fact from a log entry. The verification must be contemporaneous with the act.
• Controlled substance bulk container balance log. Maintain a running balance log for every bulk container of controlled substance ingredient. Each withdrawal must be logged with the date, amount withdrawn, remaining balance, and the compounder's initials. Periodic independent verification of the balance (weighing the container) validates the log.
• Expected yield calculation on every batch record. Before preparation begins, record the expected finished-unit yield based on the formula. After preparation, record the actual yield. Any deviation requires documented explanation — not after the fact, but at the time the discrepancy is discovered.
• Waste documentation for overages and expired preparations. All excess finished preparations and expired compounded controlled substances must go through the same waste documentation process as manufactured controlled substances — witnessed waste with contemporaneous documentation of the witnesses and quantity wasted.
• Limited access to the compounding area. Physical access to the controlled substance compounding area should be restricted to authorized personnel, logged electronically or manually, and reviewed periodically for anomalous patterns.
• Reconciliation of bulk container to finished products. Periodically reconcile the total amount of controlled substance ingredient removed from bulk containers against the total amount documented in batch records for the same period. Unexplained variance between the two is a program-level discrepancy requiring investigation.

Relationship to USP 797 and USP 800

Nonsterile compounding under USP 795 shares accountability principles with sterile compounding under USP 797 and hazardous drug handling under USP 800, but the specific workflows and discrepancy types differ. See our USP 797 guide for the diversion risks specific to IV room preparation of high-value injectables. The USP 800 guide addresses controlled substance accountability at the intersection of hazardous drug handling requirements, which applies when the compounded controlled preparation is also classified as a hazardous drug (e.g., certain antineoplastic preparations with controlled substance components).

Red Flags Specific to the Compounding Area

• A single compounder consistently produces batch yields below expected, while other compounders using the same formula produce expected yields
• Balance logs showing round-number withdrawals that do not correspond to any specific batch record
• Bulk container weights that are consistently lower than the balance log predicts when independently verified
• Compounding records completed in a single handwriting when two-person verification is required, or verified signatures added after the fact
• Expired compounded preparations that are removed from inventory without corresponding waste documentation
• A pattern of "formula losses" or "preparation waste" that consistently explains batch shortfalls at or near the upper end of what is plausible for the dosage form

Further Reading

The complete controlled substance recordkeeping framework that underlies compounding accountability is covered in our recordkeeping guide. For sterile compounding diversion risks, see the USP 797 guide, and for hazardous drug handling at the diversion intersection, see the USP 800 guide. The broader diversion prevention program framework — including surveillance design for specialty areas — is at the 10 components guide.